Pharmaceutical industry sets its sight on huge savings
Danish pharma giants Novo Nordisk and Lundbeck believe that common rules for medicine approvals could save the industry billions.
by Lone Andersen/ lone.andersen@jp.dk
In recent years the US, EU and Japan has conformed requirements for the approval of new medicine significantly and it has saved Danish pharmaceutical companies billions of kroner. But now, Novo Nordisk and Lundbeck urge authorities to go all the way and collaborate on a global scale.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
